
Oncology
Durvalumab Plus FLOT Improves Resectable Gastric Cancer
MATTERHORN found better event-free survival and pathologic response with perioperative durvalumab plus FLOT for resectable gastric or gastroesophageal junction adenocarcinoma.
Rayan Salih · September 21, 2026 · 7 min
